About Sofinnova Investments
Sofinnova Investments is a venture capital firm founded in 1974. It is primarily based out of Menlo Park, United States. As of Nov 2024, Sofinnova Investments is an active investor, having invested in 157 companies, with 1 new investment in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it led the $100M Series A round of Seaport Therapeutics along with Third Rock Ventures. This round also saw participation from Arch Venture Partners and other investors.
Overall, Sofinnova Investments portfolio has seen 34 IPOs and 66 acquisitions including key companies like Spark Therapeutics, Natera and Aclaris Therapeutics. A lot of funds co-invest with Sofinnova Investments, with names like RA Capital Management sharing a substantial percentage of its portfolio.
Sofinnova Investments has team of 25 people including 18 partners.
Key Metrics
Team Members
, &
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B &
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Sofinnova Investments' List of Top Investments
Sofinnova Investments has a portfolio of 157 companies. Their most notable investments are in Aeovian Pharmaceuticals and InCarda Therapeutics.Their portfolio spans across United States, France, United KingdomÌý²¹²Ô»å 11 more locations. They have invested in Life Sciences, High Tech, Enterprise ApplicationsÌý²¹²Ô»å 18 other sectors, across stages such as Series A, Series B Ìý²¹²Ô»å 7 more. Here is the list of top investments by Sofinnova Investments:Developer of gene therapy for rare diseases. It offers engineered adeno associated viruses to deliver the target gene sequence to the patient for RPE-65 mediated inherited retinal dystrophies. The company is also developing therapies for choroideremia, hemophilia A&B, and neurodegenerative diseases such as Batten's disease.
Key facts about Spark Therapeutics
- Founded Year: 2013
- Location: Philadelphia (United States)
- Annual Revenue: $64.7M as on Dec 31, 2018
- Stage: Acquired
- Total Funding till date: $82.8M
- Employee Count: 822 as on Dec 31, 2021
- Investors: LanceBio Ventures, Sofinnova Investments and 6 Others
- Latest Funding Round: Series B, May 23, 2014, $72.8M
- Highlight: Acquired
2. Natera
Developer of cell-free DNA testing for oncology, women’s health, and organ health. The test provided by the company inlcude Signatera– a residual disease test (MRD), Altera– tumor genomic profile, Empower– Hereditary cancer test, Prospera Kidney– transplant assessment, Panorama– Noninvasive prenatal testing (NIPT), Anora– Miscarriage Test, and more.
Key facts about Natera
- Founded Year: 2004
- Location: Redwood City (United States)
- Annual Revenue: $820M as on Dec 31, 2022
- Stage: Public
- Total Funding till date: $152M
- Employee Count: 3,293 as on Dec 31, 2023
- Investors: Sofinnova Investments, Foresite Capital and 16 Others
- Latest Funding Round: Post IPO, Apr 13, 2020, $288M
- Highlight: Public
Aclaris Therapeutics focused on the development of novel dermatologic therapies. Its lead product, A-101 is a proprietary high-concentration hydrogen peroxide topical solution being developed for the treatment of seborrheic keratosis (Phase 3). The company also is pursuing additional dermatological indications for A-101, such as the treatment of common warts (Phase 2). In Sep 2015, Aclaris acquired a portfolio of oral and topical Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions (preclinical).
Key facts about Aclaris Therapeutics
- Founded Year: 2012
- Location: Malvern (United States)
- Annual Revenue: $29.8M as on Dec 31, 2022
- Stage: Public
- Total Funding till date: $82M
- Employee Count: 180 as on Dec 31, 2022
- Investors: Aisling Capital, Frazier Healthcare Partners and 13 Others
- Latest Funding Round: Post IPO, Nov 19, 2024, $80M
- Highlight: Public
4.
Key facts about Coherus Biosciences
- Founded Year: 2010
- Location: Redwood City (United States)
- Stage: Public
- Total Funding till date: $144M
- Employee Count: 233 as on Dec 31, 2022
- Investors: Sofinnova Investments, Rock Springs Capital and
- Latest Funding Round: Post IPO, Apr 14, 2020, $200M
- Highlight: Public
Developer of therapeutics to treat seizure disorders. The company's lead candidate is Ganaxolone an intravenous (IV) and oral formulation for status epilepticus, rare orphan epilepsies, and advocacy & related activities.
Key facts about Marinus Pharma
- Founded Year: 2003
- Location: Radnor (United States)
- Annual Revenue: $15.3M as on Dec 31, 2021
- Stage: Acquired
- Total Funding till date: $71.6M
- Employee Count: 114 as on Dec 31, 2022
- Investors: Avoro Capital Advisors, Sofinnova Investments and 13 Others
- Latest Funding Round: Post IPO, Apr 04, 2022, $1.23M
- Highlight: Acquired
Sofinnova Investments' Year-on-Year Investment Trends
Sofinnova Investments has invested in 157 companies over the last 27 years, with an average of 5 new investments annually in the last 10 years. In 2024, it made 7 investments. Its most recent first time investment was in and most recent follow-on round was in Avenzo Therapeutics.
Year | No. of Investments | ||
|---|---|---|---|
1stÌý¸é´Ç³Ü²Ô»å | Follow-on | Total | |
2025 (YTD) | 0 | 0 | 0 |
2024 | 5 | 2 | 7 |
2023 | 5 | 3 | 8 |
2022 | 3 | 0 | 3 |
2021 | 3 | 4 | 7 |
2020 | 7 | 4 | 11 |
2019 | 5 | 2 | 7 |
2018 | 9 | 4 | 13 |
2017 | 9 | 4 | 13 |
2016 | 3 | 0 | 3 |
Get Sofinnova Investments' portfolio delivered to your inbox!
Sofinnova Investments' Investments by Stage
Sofinnova Investments has made 57 investments in Series A stage with an average round size of $39.6M, 39 investments in Series B stage with an average round size of $52.8M and 24 investments in Series C stage with an average round size of $60.4M.Note: We have considered here, only first round of investments
Stage of entry | No. of Investments |
|---|---|
Series A | 57 |
Series B | 39 |
Series C | 24 |
Series D | 9 |
Seed | 3 |
Others | 7 |
Sofinnova Investments' Investments by Sector
Sofinnova Investments has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, Healthcare and Sustainability Tech. Notably, it has invested in 126 Tech companies, 96 Enterprise (B2B) companies, 12 Software companies and at least 8 companies focusing on Consumer (B2C).
Note: We have considered here, only first round of investments
Sector | No. of Investments |
|---|---|
Life Sciences | 97 |
High Tech | 19 |
Enterprise Applications | 13 |
Healthcare | 13 |
Sustainability Tech | 12 |
Others | 48 |
Sofinnova Investments' Investments by Geography
Sofinnova Investments has made most investments in United States (108), followed by France where it has made 7 investments.
Note: We have considered here, only first round of investments
Country | No. of Investments |
|---|---|
United States | 108 |
France | 7 |
United Kingdom | 5 |
Denmark | 4 |
Belgium | 3 |
Others | 12 |
Sofinnova Investments' recent investments
Here are the most recent investments by Sofinnova Investments:
Date | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Nov 18, 2024 | United States | Series A | Undisclosed | Orbimed [+11] | |
Oct 18, 2024 | United States | Series B | $225M | General Atlantic [+6] | |
Oct 18, 2024 | United States | Series A | $115M | ||
Apr 09, 2024 | United States | Series A | $100M | ||
Mar 05, 2024 | United States | Series B | $175M | RA Capital Management [+13] |
Get the detailed list of all investments by Sofinnova Investments. Download now!IPOs and Publicly Listed companies in Sofinnova Investments' Portfolio
Here are Sofinnova Investments' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 26, 2024 | Feb 13, 2024 | Series D | $170M | |
Jun 07, 2024 | Aug 23, 2023 | Series B | $150M | |
Jan 26, 2024 | Dec 16, 2022 | Series B | $155M | |
Jun 30, 2021 | Aug 07, 2020 | Series A | $75.8M | |
May 14, 2021 | Oct 29, 2020 | Series C | $80M |
Acquired companies in Sofinnova Investments' Portfolio
Here are Sofinnova Investments' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 16, 2025 | Apr 10, 2019 | Series A | $67.4M | |
Feb 06, 2025 | - | - | - | |
Dec 30, 2024 | Oct 25, 2005 | Series A | $29.4M | |
Jul 17, 2024 | - | - | - | |
Jan 09, 2024 | Oct 24, 2023 | Series A | $245M |
Team profile of Sofinnova Investments
Sofinnova Investments has a team of 25 membersÌýincluding 18 Partners, 1 Venture Partner and 2 PrincipalsÌýlocated in United States, France and . Sofinnova Investments' team sits on the board of 1 company.Here is a list of top team members in Sofinnova Investments:
Name | Designation | Location | Board Memberships | Contact details |
|---|---|---|---|---|
Partner | Paris | - | ||
Partner | San Francisco | - | - | |
Partner | San Diego | - | - | |
Partner | Munich | - | - | |
Partner | Paris | - | ||
Partner | Rancho Santa Fe | - | ||
Partner | United States | - | - | |
Partner | San Francisco | - | - | |
Partner | San Diego | - | ||
Partner | London | |||
Partner | San Francisco | - | - |
Get the full list of Sofinnova Investments' team & partners for free. Download now!Co-investors of Sofinnova Investments
Over the past 27 years, 768 investors have co-invested in Sofinnova Investments's portfolio companies.
- Invested before Sofinnova Investments:ÌýOrbimed, HHS and 215 others have invested in rounds before Sofinnova Investments. There are 7 companies where Orbimed has invested before Sofinnova Investments and 7 companies where HHS has invested before Sofinnova Investments.
- Top Co-investors of Sofinnova Investments:Ìý281 investors entered a company along with Sofinnova Investments. These include investors like RA Capital Management (11 companies).
- Invested after Sofinnova Investments:ÌýA total of 270 investors have invested in Sofinnova Investments's portfolio after their investments. Top Investors include Rock Springs Capital (7 companies), RA Capital Management (6 companies) and Venrock (4 companies).
Get full list of Sofinnova Investments' co-investors delivered to your inbox!
Recent News related to Sofinnova Investments
•
•
FinSMEs•Apr 04, 2025•Atsena Therapeutics, Bain Capital Life Sciences, Wellington, Lightstone Ventures and 6 others
•
PR Newswire•Apr 02, 2025•Edgewise Therapeutics, Braidwell, Cormorant Capital, Driehaus and 14 others
•
Business Wire•Mar 18, 2025•Sofinnova Investments,
•
BioWorld•Mar 05, 2025•Sofinnova Investments
•
Portal do Agronegcio•Nov 26, 2024•Elicit Plant, Carbyne Equity Partners, Sofinnova Investments, ECBF and 2 others
•
Business Wire•Nov 18, 2024•Avenzo Therapeutics, VelaVigo, Orbimed, Foresite Capital and 13 others
•
•
intelligence360•Oct 31, 2024•Seaport Therapeutics, General Atlantic, T. Rowe Price, Foresite Capital and 7 others
•
EndPoints News•Oct 30, 2024•, Cormorant Asset Management, VenBio, Sofinnova Investments and 6 others
